Philip Joseph

Strong evidence for fixed dose combination therapies /polypill for prevention of heart attack and stroke; surgical ablation of atrial fibrillation; COVID-19 and CVD risk factors – PHRI science highlights at this year’s ESC Congress, which was virtual for the second year in a row.

Fixed dose combo/polypills cut CVD in half

PHRI Investigator Philip Joseph presented the results of a individual patient data meta-analysis of three large clinical trials (TIPS-3, HOPE-3 and PolyIran) looking at fixed dose combination therapies/polypill for primary prevention of cardiovascular disease. Simultaneously as the ESC Congress talk, The Lancet published the findings.

Download Phil’s revised ESC 2021 presentation – FDC meta-analysis.

Much commentary on Twitter happened as the results broke on August 29th, including:

Emilie Belley Cote

Surgical atrial fibrillation ablation evaluation

PHRI Investigator Emilie Belley Cote presented on a LAAOS III sub-study: surgical atrial fibrillation ablation evaulation. She concluded that concomitant surgical ablation of AF, which was not associated with a reduced risk of stroke or systemic embolism, “should focus on other patient-important outcomes.”

Download her ESC Congress presentation.

Darryl Leong

CVD risk factors and COVID-19

PHRI Scientist Darryl Leong gave an on-demand talk, cardiovascular risk factors and COVID-19 infection, discussing findings from the PURE COVID-19 sub-study he’s leading, leveraging the large global cohort of the Prospective Urban and Rural Epidemiology (PURE) study.

Download his ESC 2021 presentation here.

One of the conclusions he presented is that higher waist circumference is associated with COVID-19 independently of other characteristics (such as previous smoking, higher BMI, previous CVD, higher diastolic blood pressure, and higher serum cholesterol).

Back To Top